Healthpeak Properties, Inc.
—- Market cap
- —
- Debt
- —
- Cash
- −$467.46M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DOC stock price vs ZBH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZBH's multiple
Needs ZBH P/E.
Implied fair value · at DOC's multiple
Needs DOC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Healthpeak Properties, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ZIMMER BIOMET HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
WELLTOWER INC.
DOC vs WELL
Ventas, Inc.
DOC vs VTR
ALEXANDRIA REAL ESTATE EQUITIES, INC.
DOC vs ARE
SL GREEN REALTY CORP
DOC vs SLG
STRYKER CORP
DOC vs SYK
JOHNSON & JOHNSON
DOC vs JNJ
Medtronic plc
DOC vs MDT
Orthofix Medical Inc.
DOC vs OFIX
SMITH & NEPHEW PLC
DOC vs SNN
CONMED Corp
DOC vs CNMD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DOC can materially improve profitability and de-lever toward ZBH-like levels, then wait for a better entry or clearer turnaround evidence because the current valuation is far above both ZBH-implied and DCF ranges.
DOC trades at a material premium to ZBH on earnings, sales, and EV-based metrics, yet the provided valuation work implies meaningful downside versus the current price. The gap appears driven more by DOC’s richer multiples and weaker balance-sheet profile than by stronger operating performance.
Supporting Metrics